Geographic Atrophy Patient with Declining Vision Exploring Treatment Options

Opinion
Video

Katherine Talcott, MD, presents the case of a 64-year-old woman with geographic atrophy and a family history of age-related macular degeneration.

Supported in part by ZEISS Professional Education. Content independently developed by Eye Care Network.

Recent Videos
EnVision Summit Co-chairs Sherrol Reynolds, OD, FAAO; Katie Rachon, OD, FAAO, Dipl ABO; Jessica Steen, OD, FAAO, Dipl ABO; and Cecelia Koetting, OD, FAAO, Dipl ABO; express excitement for the upcoming conference and why optometrists should attend.
What was the biggest innovation in eye care in 2024?
Dr Carolyn Majcher chats about GA and posterior uveitis at AAOpt 2024
David Chin Yee, MD, at EyeCon 2024
Dr. Adam Wenick at EyeCon 2024
Katherine Talcott, MD, presenting slides
Emily Chew, MD, outlines her lecture that landed her the Proctor Award at ARVO 2024
Steven Ferrucci, OD, FAAO - AAOpt
Related Content
Older person's eyes Image credit: AdobeStock/yana136

2024 in the rearview: The top GA takeaways

Jordana Joy, Associate Editor;Lynda Charters
December 13th 2024
Article
Advances in treatment for geographic atrophy

Advances in treatment for geographic atrophy

David S. Boyer, MD;Tina Mac Donald, OD, CDCES, FAAO;Leo P. Semes, OD, FAAO
October 11th 2023
Podcast
FDA sign outside building Image credit: AdobeStock/JHVEPhoto

US FDA issues Complete Response Letter for avacincaptad pegol (IZERVAY)

Hattie Hayes;Jordana Joy, Associate Editor
November 19th 2024
Article
GA lesion image Image credit: AdobeStock/Dr_Microbe

Alkeus Pharmaceuticals announces topline results from SAGA trial on GA treatment

Jordana Joy, Associate Editor
October 25th 2024
Article
Patient sitting for OCT scan Image credit: AdobeStock/elenavolf

Study suggests that small hyperreflective retinal foci may represent local neuroretinal inflammation

Lynda Charters
October 7th 2024
Article
Enrollment complete of phase 2b of SIGLEC study to assess safety and efficacy of AVD-104 for GA secondary to AMD

Enrollment complete of phase 2b of SIGLEC study to assess safety and efficacy of AVD-104 for GA secondary to AMD

Lynda Charters
September 30th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.